公开(公告)号：US20230011699A1

公开(公告)日：2023-01-12

申请号：US17860609

申请日：2022-07-08

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Matthew ALLES ,  Yibin ZHENG ,  Jason O'CONNOR

IPC: A61M5/172

Abstract: Provided are techniques, devices and systems that include monitoring a trend of blood glucose measurement values over a series of measurement cycles. A processor may identify a potential excursion outside a range of a target blood glucose measurement value setting of a user based on the monitored trend. In response to the identified potential excursion, an alert may be generated to the user to consume rescue carbohydrates. In addition, the disclosed techniques may include a processor that assesses the factors related to a potential impending hypoglycemic event for a user. Based on a result of the assessment of the factors, the processor may determine whether the user is approaching the potential impending hypoglycemic event for the user. In response to a determination that the user is approaching the potential impending hypoglycemic event for the user, a number of rescue carbohydrates to suggest for consumption by the user may be determined.

公开(公告)号：US20220241504A1

公开(公告)日：2022-08-04

申请号：US17582349

申请日：2022-01-24

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Jason O'CONNOR ,  Yibin ZHENG ,  Ashutosh ZADE

IPC: A61M5/172 ,  G16H20/17

Abstract: Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.

公开(公告)号：US20220240847A1

公开(公告)日：2022-08-04

申请号：US17582374

申请日：2022-01-24

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Jason O'CONNOR ,  Yibin ZHENG ,  Ashutosh ZADE

IPC: A61B5/00 ,  A61B5/145 ,  A61K38/22 ,  G16H20/17 ,  G16H40/67

Abstract: Disclosed herein are systems and methods for the delivery of insulin and pramlintide using an automated insulin delivery system. In a first embodiment, a drug delivery system is configured to deliver independent doses of insulin and pramlintide. The system monitors the user's blood glucose level and determines when a meal is been ingested and, in response, delivers the dose of pramlintide which, in turn alters the required delivery of insulin. In the second embodiment, the drug delivery system is configured to deliver a co-formulation of insulin and pramlintide as basal doses. The total amount of pramlintide delivered in a most recent pre-determine period of time, for example, 24 hours, is used to alter the aggressiveness of the algorithm which determines the basal doses of the co-formulation.

公开(公告)号：US20210236726A1

公开(公告)日：2021-08-05

申请号：US16780278

申请日：2020-02-03

Applicant: Insulet Corporation

Inventor： Steven CARDINALI ,  Ashutosh ZADE ,  Joon Bok LEE ,  Jason O'CONNOR ,  Yibin ZHENG

IPC: A61M5/172

Abstract: Exemplary embodiments may provide an improved approach to automated insulin delivery by more accurately estimating the total daily insulin (TDI) of a user. As a result, less insulin is wasted by the delivery system, and the estimate of TDI more closely matches a user's actual daily insulin needs. Hence, the user need not refill the insulin reservoir excessively or need not fret unnecessarily about running out of insulin prematurely. The estimate relies on the history of actual automated insulin deliveries and thus reflects the actual insulin delivered to the user more accurately than conventional approaches.

公开(公告)号：US20210098105A1

公开(公告)日：2021-04-01

申请号：US16586499

申请日：2019-09-27

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR ,  Trang LY ,  Eric BENJAMIN

IPC: G16H20/17 ,  A61M5/172

Abstract: Disclosed are a device, a computer-readable medium, and techniques that provide an onboarding process and an adaptivity process for a drug delivery device. A processor executing an onboarding process determines whether a history of delivered insulin to a user meets certain sufficiency requirements. The onboarding process enables a processor to cause the drug delivery device to administer doses of insulin to a user according to an initial total daily insulin dose calculation that is determined based on the sufficiency of the insulin delivery history. The initial total daily insulin may be adapted according to the adaptivity process as new insulin delivery is collected. The insulin delivery history, when sufficient, may be used to set total daily insulin dosages that enable automated insulin delivery upon replacement of a drug delivery device. The adaptivity process may be implemented to modify an initial insulin delivery doses to provide adapted insulin delivery doses.

公开(公告)号：US20190336683A1

公开(公告)日：2019-11-07

申请号：US16402753

申请日：2019-05-03

Applicant: Insulet Corporation

Inventor： Jason O'CONNOR ,  Joon Bok LEE ,  Trang LY ,  Yibin ZHENG ,  Thomas Arnold PEYSER ,  Jennifer Lena SCHNEIDER

IPC: A61M5/172 ,  A61M5/142 ,  A61M5/145 ,  A61B5/145

Abstract: Disclosed are a system, methods and computer-readable medium products that provide safety constraints for an insulin-delivery management program. Various examples provide safety constraints for a control algorithm-based drug delivery system that provides automatic delivery of a drug based on sensor input. Glucose measurement values may be received at regular time intervals from a sensor. A processor may predict future glucose values based on prior glucose measurement values. The safety constraints assist in safe operation of the drug delivery system during various operational scenarios. In some examples, predicted future glucose values may be used to implement safety constraints that mitigate under-delivery or over-delivery of the drug while not overly burdening the user of the drug delivery system and without sacrificing performance of the drug delivery system. Other safety constraints are also disclosed.